Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ASIC3 | Q9UHC3 | 2/20 | 0.55 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.55 |
| ▸ | LMNA | P02545 | 4/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | MAP4K4 | O95819 | 3/20 | 0.55 |
| ▸ | MAPT | P10636 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.54 |
| ▸ | RAB9A | P51151 | 1/20 | 0.54 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | POLB | P06746 | 2/20 | 0.51 |
| ▸ | GFER | P55789 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | CCR1 | P32246 | 2/20 | 0.50 |
| ▸ | CCR5 | P51681 | 2/20 | 0.50 |
| ▸ | CCR8 | P51685 | 2/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29851729 | 1.00 | ASIC3 (0.55) | ASIC3KDM4ELMNAALDH1A1MEN1 | |
| SCHEMBL502867 | 0.85 | KDM4E (0.62) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL29679578 | 0.85 | KDM4E (0.62) | KDM4ELMNAALDH1A1MAPTHPGD | |
| SCHEMBL30679410 | 0.85 | MAOB (0.56) | ASIC3KDM4ELMNAALDH1A1MEN1 | |
| Imidazole SCHEMBL28793335 | 0.84 | HRH3 (0.45) | ASIC3KDM4ELMNAALDH1A1MEN1 | |
| SCHEMBL9225779 | 0.84 | KDM4E (0.55) | ASIC3KDM4ELMNAALDH1A1MEN1 | |
| SCHEMBL29720253 | 0.83 | KDM4E (0.54) | ASIC3KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL12436470 | 0.83 | KDM4E (0.54) | ASIC3KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL12444511 | 0.83 | KDM4E (0.54) | ASIC3KDM4ELMNAALDH1A1MAPT | |
| SCHEMBL18745791 | 0.83 | PIK3CD (0.49) | ASIC3KDM4ELMNAALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 229 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PSOMAGEN, INC. (US) | 2022-08-23 | — | — | US | claimed |
| CN-109148796-B | Acid scavenging functional diaphragm for lithium ion electrochemical cell functional performance | 通用汽车环球科技运作有限责任公司 | 2022-01-25 | — | — | CN | claimed |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MACROGEN INC. (KR) | 2021-05-06 | — | — | US | claimed |
| US-10741812-B2 | Acid-scavenging functional separators for power performance of lithium ion electrochemical cells | GM Global Technology Operations LLC (US) | 2020-08-11 | — | — | US | claimed |
| EP-3668494-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | Psomagen, Inc. (US) | 2020-06-24 | — | — | EP | claimed |
| WO-2019036507-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | uBiome, Inc. (US) | 2019-02-21 | — | — | WO | claimed |
| US-20190050525-A1 | RIESKE-TYPE OXYGENASE/REDUCTASE TARGETED DRUGS FOR DIAGNOSTIC AND TREATMENT OF DISEASES | PSOMAGEN, INC. | 2019-02-14 | — | — | US | claimed |
| CN-109148796-A | Acid for lithium ion electrochemical cells power-performance removes function diaphragm | 通用汽车环球科技运作有限责任公司 | 2019-01-04 | — | — | CN | claimed |
| US-20180366781-A1 | ACID-SCAVENGING FUNCTIONAL SEPARATORS FOR POWER PERFORMANCE OF LITHIUM ION ELECTROCHEMICAL CELLS | GM Global Technology Operations LLC | 2018-12-20 | — | — | US | claimed |
| EP-1451160-B1 | PYRAZOLE-AMIDES FOR USE IN THE TREATMENT OF PAIN | ICAGEN INC (US) | 2010-01-13 | — | — | EP | claimed |
| EP-0880531-B1 | SUBSTITUTED 2-PHENYLPYRIDINES | BASF AG (DE) | 2001-06-20 | — | — | EP | claimed |
| EP-3860636-B1 | MATRIPTASE 2 INHIBITORS AND USES THEREOF | DISC MEDICINE INC (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4638441-A1 | GLYCINE DERIVATIVES WITH P2X4 RECEPTOR-BLOCKING ACTIVITY AS DIAGNOSTICS AND FOR THE TREATMENT OF PAIN, INFLAMMATION, CANCER, AND OTHER P2X4 RECEPTOR-RELATED DISEASES | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2025-10-29 | — | — | EP | disclosed |
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | DISC MEDICINE, INC. (US) | 2025-09-30 | — | — | US | disclosed |
| US-20250263404-A1 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | UCL BUSINESS LTD (GB) | 2025-08-21 | — | — | US | disclosed |
| US-4075217-A | Conversion of 3-(pyridinyl)-2-cyclohexen-1-one to 3-(pyridinyl)anilines | STERLING DRUG INC. (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075217-A | Conversion of 3-(pyridinyl)-2-cyclohexen-1-one to 3-(pyridinyl)anilines | STERLING DRUG INC. (US) | 1978-02-21 | — | — | US | disclosed |
| US-4075217-A | Conversion of 3-(pyridinyl)-2-cyclohexen-1-one to 3-(pyridinyl)anilines | STERLING DRUG INC. (US) | 1978-02-21 | — | — | US | disclosed |
| US-4026900-A | 3-(Pyridinyl)-2-cyclohexen-1-ones | STERLING DRUG INC. (US) | 1977-05-31 | — | — | US | disclosed |
| US-4026900-A | 3-(Pyridinyl)-2-cyclohexen-1-ones | STERLING DRUG INC. (US) | 1977-05-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12428415-B2 | Matriptase 2 inhibitors and uses thereof | MMP7, MATR3, SPINT2 | ASIC3 2504/4885KDM4E 1948/4885LMNA 1207/4885 |
| US-11424006-B2 | Targeted drugs associated with trimethylamine and/or trimeihylamine-n-oxide | PNMT, MAOA, HNMT | ASIC3 2567/4885KDM4E 733/4885LMNA 2593/4885 |
| US-20210128498-A1 | TARGETED DRUGS ASSOCIATED WITH TRIMETHYLAMINE AND/OR TRIMETHYLAMINE-N-OXIDE | MAOA, PNMT, HNMT | ASIC3 1249/4885KDM4E 1224/4885LMNA 2828/4885 |
| US-20250263404-A1 | AMINOPYRIDINES AS ACTIVATORS OF PI3 KINASE | PIK3CD, PTEN, PIK3CG | ASIC3 1005/4885KDM4E 2895/4885LMNA 3222/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.